.png){kind=icon}
.png){kind=icon}
Return
Combination of KRASG12C targeted adagrasib with anti-PD-1 immune-checkpoint inhibitor to improve overall survival and prevent recurrence in preclinical models of brain metastasis
.png){kind=icon}
OA
AI
C
N
G
A
M
C
E
N
E
B
E
V
L
B
P
H
P
DOI：10.1093/noajnl/vdag107.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Despite advances in treatment, brain metastasis (BM) management remains a significant challenge. Adagrasib is a brain-penetrant KRASG12C inhibitor active in patients with BM. KRAS mutations are linked with immune escape and may contribute to the limited clinical benefit from single-agent immune checkpoint inhibitors (ICI) targeting PD-1/PD-L1 in BM. Although adagrasib sensitizes extracranial tumors to ICI, its intracranial benefit combined with immunotherapy remains unknown. Here, we evaluate adagrasib with ICI in mouse models that mimic the BM immune microenvironment.
Journal
N
IF:
4.1
Papers:
1.5K
Citations:
3.2K
Organization
Cited Papers